Ledger.Open graph →
SEC Form D · filed March 30, 2021

Nacuity Pharmaceuticals, Inc

Offering
$11.0M
Sold
$3.2M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
FORT WORTH, TX
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (21)

Robert Ruffolo · Fort Worth, TXDirectorGerald Cagle · Fort Worth, TXDirectorDavid Wohlberg · Fort Worth, TXExec · DirectorHalden Conner · Fort Worth, TXExec · DirectorCharles Lieser · Fort Worth, TXExecBenjamin Yerxa · Fort Worth, TXDirectorRobin Steel · Fort Worth, TXDirectorPeter G. Davies · Columbus, OHDirectorThomas R. Utgard · Columbus, OHDirectorRochael Adranly · San Francisco, CAExec · Director(General Partner) Poplar Forest Capital LLC · Pasadena, CADirectorStonehenge Partners Corp · Columbus, OHExec · DirectorJack Mitchell · Gladstone, MOExecAndrew F. Bohutinsky · Columbus, OHDirectorSteve Carpenter · Boulder, COExec · DirectorLaurence P. Sellyn · Village of Golf, FLExecSound Point Meridian Fund GP LLC · New York, NYDirectorVincent Molinari · Woodbury, NYExec · DirectorKavita Gupta · Woodbury, NYDirectorThomas Krane · Somerville, MADirectorNiloofar Howe · Somerville, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗